Rallybio Reports Positive Data For RLYB116 Phase 1 Study

February 17, 2026 — 08:30 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Rallybio (RLYB) announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic clinical trial evaluating RLYB116, the company's once-weekly, small volume, subcutaneously injected C5 inhibitor, in development for patients with complement-mediated diseases with its initial focus on immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. A 300 mg once-a-week dose of subcutaneously administered RLYB116 achieved complete and sustained inhibition of terminal complement.

"Based on our prior clinical experience, the Phase 1 results are compelling and provide strong corroboration for our scientific and clinical rationale," said Steven Ryder, Chief Medical Officer of Rallybio.

In pre-market trading on NasdaqCM, Rallybio shares are down 5.81 percent to $4.54.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Rallybio Reports Positive Data For RLYB116 Phase 1 Study

Tags

Latest Articles